Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes

Table 3 Multivariate logistic regression analysis on worsening of glycemic control after omarigliptin administration

	Odds ratio	95%CI	P value
Sex (male)	0.837	0.03-24.30	NS
Age	1.004	0.82-1.23	NS
Insulin secretagogues1 use	0.575	0.04-7.72	NS
Insulin use	0.038	0.001-1.460	NS
BMI at omarigliptin administration	0.757	0.45-1.26	NS
eGFR at omarigliptin administration	0.941	0.84-1.06	NS
HbA1c at omarigliptin administration	5.862	0.86-39.80	NS
Switching from vildagliptin	146.62	7.00-3072.60	0.0013

¹Insulin secretagogues include sulfonylurea and glinide, but not dipeptidyl peptidase-4 inhibitor.

BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; NS: Not significant; CI: Confidence interval.